Mode
Text Size
Log in / Sign up
N/A Completed N=300 Randomized Other

Dynamically Tailored Behavioral Interventions in Diabetes

Type 2 Diabetes
Source: ClinicalTrials.gov NCT04226027 ↗
Enrolled (actual)
300
Serious AEs
2.7%
Results posted
May 2026
Primary outcomePrimary: Mean HbA1c Value — 9.84; 10.17; 8.91; 9.23 % of hemoglobin bound to glucose — p=0.0085

Summary

In this project, the investigators will evaluate the efficacy of a novel approach to personalizing behavioral interventions for self-management of type 2 diabetes (T2DM) to individuals' behavioral and glycemic profiles discovered using computational learning and self-monitoring data. This study is a two-arm randomized controlled trial with n=280 participants recruited from the participating Federally Qualified Health Centers (FQHCs). The participants will be randomly assigned to the intervention group and the usual care (control) group with 1-1 allocation ratio. Half of the participants (n=140) will be randomly assigned to a usual care (control) group. Both groups will receive standard diabetes education at their respective FQHC site. In addition, the experimental group will receive instructions to use T2.coach for a minimum of 6 months.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean HbA1c Value
9.84; 10.17; 8.91; 9.23; 8.72; 9.32 0.0085 sig
SECONDARY
SCA-I Score
65.54; 68.86; 73.89; 74.75; 73.81; 74.16 0.83
SECONDARY
DSES Score
5.73; 5.91; 5.98; 6.14; 6.27; 6.05 0.18
SECONDARY
PAID Score
29.62; 31.16; 26.24; 23.81; 26.43; 25.2 0.68

Eligibility Criteria

Inclusion Criteria

  • Patient of the health center for ≥ 6 months and a diagnosis of T2DM
  • HbA1c ≥ 8.0,
  • Aged 18 to 65 years
  • Attends diabetes education program at the health center
  • Owns a basic mobile phone
  • Proficient in either English or Spanish

Exclusion Criteria

  • Pregnant
  • Presence of severe cognitive impairment (recorded in patient chart),
  • Existence of other serious illnesses (e.g. cancer diagnosis with active treatment, advanced stage heart failure, dialysis, multiple sclerosis, advanced retinopathy, recorded in patient chart),
  • Plans for leaving the FQHC in the next 12 months,
  • Participation in the previous trial of diabetes self-management technologies
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04226027). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search